Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least one Prior Therapy (20200445)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/50712
• EU PAS number:
  EUPAS49271
• Study ID:
  50712
• Official title and acronym:
  Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least one Prior Therapy (20200445)
• DARWIN EU® study:
  No
• Study countries:
  Finland

  France

  Germany

  Greece

  Italy

  Portugal

  Spain
• Study status:
  Cancelled

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 27/07/2021

Study start date

Planned: 23/01/2024

Data analysis start date

Planned: 22/01/2026

Date of final study report

Planned: 08/07/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable